NICE green light helps Merck offer RA patients wider treatment choice
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has today published final and binding guidance recommending Merck & Co's subcutaneous anti-TNF-alpha monoclonal antibody Simponi (golimumab), in combination with methotrexate, for treating some patients with rheumatoid arthritis (RA).